JP2009521494A5 - - Google Patents

Download PDF

Info

Publication number
JP2009521494A5
JP2009521494A5 JP2008547727A JP2008547727A JP2009521494A5 JP 2009521494 A5 JP2009521494 A5 JP 2009521494A5 JP 2008547727 A JP2008547727 A JP 2008547727A JP 2008547727 A JP2008547727 A JP 2008547727A JP 2009521494 A5 JP2009521494 A5 JP 2009521494A5
Authority
JP
Japan
Prior art keywords
composition
alkyl
independently
membered ring
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008547727A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009521494A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/062307 external-priority patent/WO2007076360A1/en
Publication of JP2009521494A publication Critical patent/JP2009521494A/ja
Publication of JP2009521494A5 publication Critical patent/JP2009521494A5/ja
Pending legal-status Critical Current

Links

JP2008547727A 2005-12-22 2006-12-19 rhoキナーゼ媒介性疾患および状態を治療するための(インダゾール−5−イル)−ピラジンおよび(1,3−ジヒドロインドール−2−オン)−ピラジン Pending JP2009521494A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75313605P 2005-12-22 2005-12-22
PCT/US2006/062307 WO2007076360A1 (en) 2005-12-22 2006-12-19 (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions

Publications (2)

Publication Number Publication Date
JP2009521494A JP2009521494A (ja) 2009-06-04
JP2009521494A5 true JP2009521494A5 (cg-RX-API-DMAC10.html) 2011-02-03

Family

ID=37963712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008547727A Pending JP2009521494A (ja) 2005-12-22 2006-12-19 rhoキナーゼ媒介性疾患および状態を治療するための(インダゾール−5−イル)−ピラジンおよび(1,3−ジヒドロインドール−2−オン)−ピラジン

Country Status (14)

Country Link
US (1) US7655662B2 (cg-RX-API-DMAC10.html)
EP (1) EP1962853A1 (cg-RX-API-DMAC10.html)
JP (1) JP2009521494A (cg-RX-API-DMAC10.html)
KR (1) KR20080077652A (cg-RX-API-DMAC10.html)
CN (1) CN101340912A (cg-RX-API-DMAC10.html)
AR (1) AR058618A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0620463A2 (cg-RX-API-DMAC10.html)
CA (1) CA2629342A1 (cg-RX-API-DMAC10.html)
MX (1) MX2008008328A (cg-RX-API-DMAC10.html)
RU (1) RU2008130111A (cg-RX-API-DMAC10.html)
TW (1) TW200733964A (cg-RX-API-DMAC10.html)
UY (1) UY30058A1 (cg-RX-API-DMAC10.html)
WO (1) WO2007076360A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200804497B (cg-RX-API-DMAC10.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2580108T3 (es) * 2005-07-11 2016-08-19 Aerie Pharmaceuticals, Inc Compuestos de isoquinolina
US20070135499A1 (en) * 2005-07-11 2007-06-14 Aerie Pharmaceuticals, Inc. Hydrazide compounds
EP2526948A1 (en) 2006-09-20 2012-11-28 Aerie Pharmaceuticals, Inc. RHO kinase inhibitors
CA2663436A1 (en) * 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
EP2299820A4 (en) * 2008-06-18 2012-11-14 Inspire Pharmaceuticals Inc OPHTHALMOLOGICAL FORMULATION OF RHO KINASE INHIBITOR COMPOUND
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
KR101712576B1 (ko) 2008-11-10 2017-03-06 버텍스 파마슈티칼스 인코포레이티드 Atr 키나제의 억제제로서 유용한 화합물
PL3354650T3 (pl) 2008-12-19 2022-06-13 Vertex Pharmaceuticals Incorporated Związki przydatne jako inhibitory kinazy atr
WO2010126626A2 (en) 2009-05-01 2010-11-04 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
JP5739448B2 (ja) 2009-12-21 2015-06-24 アレイ バイオファーマ、インコーポレイテッド cFMS阻害剤としての置換N−(1H−インダゾール−4−イル)イミダゾ[1,2−a]ピリジン−3−カルボキサミド化合物
WO2011143423A2 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2013526538A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
JP5836367B2 (ja) 2010-05-12 2015-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Atrキナーゼ阻害剤として有用な化合物
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
US9096584B2 (en) 2010-05-12 2015-08-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2013529643A (ja) 2010-06-23 2013-07-22 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用なピロロピラジン誘導体
CA2832100A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2014522818A (ja) 2011-06-22 2014-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
WO2012178123A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
IN2014KN00943A (cg-RX-API-DMAC10.html) 2011-09-30 2015-08-21 Vertex Pharma
RU2018147217A (ru) 2011-09-30 2019-01-18 Вертекс Фармасьютикалз Инкорпорейтед Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
AU2012315384B2 (en) 2011-09-30 2017-08-10 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors
EP2776421A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776429A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN104582795B (zh) 2012-04-05 2018-04-20 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
LT3418281T (lt) 2012-12-07 2021-01-11 Vertex Pharmaceuticals Inc. Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
ES2776199T3 (es) 2013-03-15 2020-07-29 Aerie Pharmaceuticals Inc Conjugados de compuestos de isoquinolina y prostaglandinas
US9328200B2 (en) * 2013-07-17 2016-05-03 Ultrasci Discovery Llp Branched polymeric quaternary ammonium compounds and their uses
HUE046727T2 (hu) 2013-12-06 2020-03-30 Vertex Pharma Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
ES2777608T3 (es) 2014-06-05 2020-08-05 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
WO2017086941A1 (en) 2015-11-17 2017-05-26 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
WO2018045091A1 (en) 2016-08-31 2018-03-08 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
CA3057872A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2021247690A1 (en) * 2020-06-03 2021-12-09 Glaukos Corporation Rho kinase inhibitor releasing implants and related methods of use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0492903A1 (en) * 1990-12-21 1992-07-01 MERCK SHARP & DOHME LTD. Substituted pyrazines, pyrimidines and pyridazines for use in the treatment of glaucoma
JP3719609B2 (ja) * 1995-12-21 2005-11-24 アルコン ラボラトリーズ,インコーポレイテッド 緑内障および眼虚血の治療のための特定のイソキノリンスルホニル化合物の使用
US5798380A (en) * 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
US6586425B2 (en) * 1996-02-21 2003-07-01 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
PT956865E (pt) * 1996-08-12 2007-07-30 Mitsubishi Pharma Corp Medicamentos compreendendo inibidores da rho cinase.
CA2214841A1 (en) 1997-10-31 1999-04-30 Lisa Mckerracher Rho antagonists and their use to block inhibition of neurite outgrowth
KR100616466B1 (ko) * 1998-08-17 2006-08-29 센주 세이야꾸 가부시키가이샤 녹내장 예방/치료제
AU4144400A (en) * 1999-04-27 2000-11-10 Mitsubishi Pharma Corporation Preventives/remedies for liver diseases
JP3430254B2 (ja) 2000-03-13 2003-07-28 独立行政法人産業技術総合研究所 β−ジケトナートを有する金属錯体及びその製法、光電変換素子並びに、光化学電池
ES2266171T3 (es) 2000-03-16 2007-03-01 Mitsubishi Pharma Corporation Compuestos de amida y su uso.
JP4776138B2 (ja) * 2000-03-31 2011-09-21 田辺三菱製薬株式会社 腎臓疾患予防・治療剤
EP1403255A4 (en) 2001-06-12 2005-04-06 Sumitomo Pharma RHO KINASE INHIBITORS
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
EP1465900B1 (en) 2002-01-10 2008-05-14 Bayer HealthCare AG Rho-kinase inhibitors
CA2473910C (en) 2002-01-23 2011-03-15 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
AU2003281623B8 (en) 2002-07-22 2009-06-11 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivative
CA2502583A1 (en) 2002-09-12 2004-03-25 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinase inhibitory activity and medicament containing the same
WO2004084824A2 (en) 2003-03-24 2004-10-07 Merck & Co., Inc. Biaryl substituted 6-membered heterocyles as sodium channel blockers
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
EP1644365A2 (en) * 2003-07-02 2006-04-12 Biofocus Discovery Ltd Pyrazine and pyridine derivatives as rho kinase inhibitors
US7390907B2 (en) * 2003-09-30 2008-06-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP1830853B1 (en) * 2004-12-27 2011-08-10 Novartis AG Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases

Similar Documents

Publication Publication Date Title
ES2601820T5 (es) Moduladores de propiedades terapéutica de las farmacocinéticas
US11512060B2 (en) 1,2,4-oxadiazole derivatives as immunomodulators
RU2008130111A (ru) (индазол-5-ил)пиразины и (1,3-дигидроиндол-2-он)пиразины для лечения опосредованнызх rно-киназой заболеваний и состояний
JP5524181B2 (ja) 治療剤としての置換ガンマラクタム
CA2590261A1 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
ES3026665T3 (en) Modulators of pharmacokinetic properties of therapeutics
JP5918848B2 (ja) ベンゾチアゾール化合物およびその薬学的使用
TWI500616B (zh) 新穎之雙環吡啶酮
KR101640263B1 (ko) 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
CN107105660A (zh) 使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法
JP2003532731A5 (cg-RX-API-DMAC10.html)
JP2003501474A5 (cg-RX-API-DMAC10.html)
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
JP2003509349A5 (cg-RX-API-DMAC10.html)
JP2006507220A5 (cg-RX-API-DMAC10.html)
EA037327B1 (ru) Соединения и композиции для лечения глазных расстройств
JP2020023504A (ja) マラリアの治療のための化合物及び方法
CA2488001A1 (en) 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma
RU2011108485A (ru) Новые (поли)аминоалкиламиноалкиламидные, алкилмочевинные или алкилсульфонамидные производные эпиподофиллотоксина, способ их получения и их применение в терапии в качестве противораковых средств
JP2009525970A (ja) α2−アドレナリン受容体アゴニストとしてのアプラクロニジンおよびブリモドニジンのニトロオキシ含有誘導体
CA2589744A1 (en) Pyrrolinidium derivatives as m3 muscarinic receptors
JP2022529814A5 (cg-RX-API-DMAC10.html)
JP2013522321A (ja) Hivを治療するためのccr5モジュレーター
JP2004538278A5 (cg-RX-API-DMAC10.html)
CN1297431A (zh) 用作多巴胺受体的苯磺酰胺-苯乙胺